Gilead to Develop Hepatitis B Therapies Using Precision's ARCUS Genome Editing Platform

Gilead Sciences will use Precision BioScience’s ARCUS genome editing platform to develop therapies targeting the in vivo elimination of hepatitis B virus (HBV) under a collaboration that could generate more than $445 million for Precision, the companies said.The companies cited preliminary studies at Gilead using ARCUS nucleases to target HBV covalently closed circular DNA (cccDNA) in vitro , which they said have shown “significant” activity against cccDNA and integrated HBV DN